证券代码：688151 证券简称：华强科技 公告编号：2025-024 湖北华强科技股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩 说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 5 月 27 日（星期二）10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于 2025 年 5 月 20 日（星期二）至 5 月 26 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （office@hqtc.com）进行提问。公司将在业绩说明会上对投资者普遍关注的问题 进行回答。 三、参加人员 公司出席本次业绩说明会的人员包括：董事长、党委书记孙光幸先生，董事、 总经理、党委副书记刘榜劳先生，总会计师、总法律顾问、首席合规官孙岩先生， 独立董事刘洪川先生 ...

证券代码：688151 证券简称：华强科技 公告编号：2025-023 湖北华强科技股份有限公司 2024年年度股东大会决议公告 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 136 | | --- | --- | | 普通股股东人数 | 136 | | 2、出席会议的股东所持有的表决权数量 | 267,967,302 | | 普通股股东所持有表决权数量 | 267,967,302 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 77.7844 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 77.7844 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 1 1、本次股东大会所采用的表决方式是现场投票和网络投票相结合的方式。 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一 ...

* & is Dentons' Preferred Law Firm in 北京士成(宜昌)律师事务所 湖北省宜昌市西陵区夷陵大道 72 号 州大厦 A 座 14-16 层 邮编:443000 Beijing Dacheng Law Offices, LLP(Yichang) 14-16 F. Tower A. Jiuzhou Building No 72 Yiling Avenue, Xiling District 443000, Yichang, Hubei, China 北京大成(宜昌)律师事务所 关于湖北华强科技股份有限公司 2024 年年度股东大会的 法 律 意 见 书 大成 is Dentons'Preferred Law Firm in China. 北京大成(宜昌)律师事务所 www.dacheng.com 湖北省宜昌市西陵区夷陵大道 72 号九州大厦 A 座 14-16 层 (443000) 14-16 F, Tower A, Jiuzhou Building No.72, Yiling Avenue, Xiling District ,443000, Yichang, Hubei, Chi ...

Group 1 - The core viewpoint of the report is to summarize the sponsorship and regulatory compliance of Hubei Huqiang Technology Co., Ltd. during its initial public offering (IPO) on the Sci-Tech Innovation Board [1] - The issuer, Hubei Huqiang Technology Co., Ltd., has a registered capital of 344.5 million yuan and was listed on December 6, 2021 [1] - The report outlines the responsibilities of the sponsor, Huatai United Securities, including due diligence, document preparation, and compliance with regulatory requirements [1][3] Group 2 - The net amount raised from the IPO was 2.8121508 billion yuan, allocated to various projects including the "New Nuclear Biochemical Emergency Rescue Protection Equipment Industrialization Production Base Project" [4] - As of 2024, the balance of the special account for raised funds was 1.69612742 billion yuan, which includes idle funds used for cash management [4] - The sponsor has issued independent opinions on the use of raised funds for the years 2021, 2022, and 2023, confirming compliance with relevant regulations and no violations in fund usage [6][7][13] Group 3 - The report details the continuous supervision activities conducted by the sponsor, including on-site inspections and reviews of the issuer's governance and fund usage [3][4] - The sponsor has issued 24 verification opinions during the supervision period, with no disapprovals noted [8] - The issuer has been responsive to regulatory inquiries and has made necessary corrections regarding financial reporting and fund management [10][11]

| 保荐机构名称：华泰联合证券有限责任公司 | 被保荐公司简称：华强科技 | | --- | --- | | 保荐代表人姓名：刘伟 | 联系电话：021-38966588 | | 保荐代表人姓名：张展培 | 联系电话：010-56839300 | 根据《证券法》《证券发行上市保荐业务管理办法》和《上海证券交易所科 创板股票上市规则》等有关法律、法规的规定，华泰联合证券有限责任公司（以 下简称"华泰联合证券"或"保荐机构"）作为湖北华强科技股份有限公司（以 下简称"华强科技"或"公司"）首次公开发行股票并在科创板上市项目的保荐 机构，对华强科技进行持续督导，并出具本持续督导跟踪报告。 华泰联合证券有限责任公司 关于湖北华强科技股份有限公司 2024 年度持续督导跟踪报告 一、保荐机构和保荐代表人发现的问题及整改情况 （一）募集资金投资项目进展不及预期 截至2024年末，公司募投项目新型核生化应急救援防护装备产业化生产基地 项目（以下简称"生产基地项目"）、新型核生化防护基础材料研发平台建设项 目（以下简称"研发平台项目"）和信息化（数据驱动的智能企业）建设项目（以 下简称"信息化项目"）的募集资金累计投入进度分 ...

关于湖北华强科技股份有限公司 首次公开发行股票并在科创板上市 之保荐总结报告书 | 保荐机构名称 | 华泰联合证券有限责任公司 | | --- | --- | | 保荐机构编号 | Z26774000 | 一、保荐机构及保荐代表人承诺 保荐总结报告书 华泰联合证券有限责任公司 1、保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误导 性陈述或重大遗漏，保荐机构及保荐代表人对其真实性、准确性、完整性承担法 律责任。 2、本机构及本人自愿接受中国证券监督管理委员会（以下简称"中国证监 会"）、上海证券交易所对保荐总结报告书相关事项进行的任何质询和调查。 3、本机构及本人自愿接受中国证监会按照《证券发行上市保荐业务管理办 法》的有关规定采取的监管措施。 二、保荐机构基本情况 | 情况 | 内容 | | --- | --- | | 保荐机构名称 | 华泰联合证券有限责任公司 | | 注册地址 | 深圳市前海深港合作区南山街道桂湾五路 128 号前海深港基金小 | | | 镇 栋 B7 401 | | 主要办公地址 | 北京市西城区丰盛胡同 22 号丰铭国际大厦 A 座 6 层 | | 法定代表人 | 江禹 ...

Group 1 - The core viewpoint of the news is that the military equipment restructuring concept has seen a significant increase of 5.31%, leading the concept sector in terms of growth [1][2] - Within the military equipment restructuring concept sector, seven stocks experienced gains, with Hunan Tianyan and Construction Industry hitting the daily limit, while Changcheng Military Industry, Dong'an Power, and Huachuang Technology also showed notable increases of 6.23%, 5.46%, and 4.49% respectively [1][2] Group 2 - The military equipment restructuring concept sector attracted a net inflow of 423 million yuan from main funds today, with six stocks receiving net inflows [2][3] - The stock with the highest net inflow was Construction Industry, which saw a net inflow of 261 million yuan, followed by Hunan Tianyan, Changcheng Military Industry, and Dong'an Power with net inflows of 81.57 million yuan, 53.78 million yuan, and 16.46 million yuan respectively [2][3] - In terms of fund inflow ratios, Construction Industry, Hunan Tianyan, and Huachuang Technology had the highest net inflow rates of 19.42%, 18.58%, and 9.71% respectively [3]

Core Viewpoint - The pharmaceutical packaging industry in China is experiencing steady growth, with the market size expected to reach 143.96 billion yuan in 2024, driven by the expansion of the domestic pharmaceutical market and increasing demand for medicines due to aging population and improved healthcare systems [1][11]. Industry Definition and Classification - Pharmaceutical packaging refers to a range of materials and containers used to protect medicines, facilitate storage and transportation, promote sales, provide drug information, and ensure medication safety [2]. Industry Chain Analysis - The pharmaceutical packaging industry chain includes multiple sectors: raw material supply, packaging material manufacturing, drug packaging and application, and auxiliary services. The upstream involves the supply of materials like plastics, glass, metals, and paper, which are crucial for the manufacturing of packaging materials [3]. Industry Development History - The development of the pharmaceutical packaging industry in China has gone through three stages: initial development, rapid expansion, and transformation and innovation. The industry has evolved from relying on imports to adopting advanced technologies and focusing on brand building and market expansion [6]. Current Industry Status - China is the world's largest producer of plastic products, with a production volume of 77.08 million tons in 2024. The availability and pricing of plastic products directly impact the pharmaceutical packaging industry [9][11]. Market Structure - The market structure of the pharmaceutical packaging industry is diverse, with plastic packaging holding a 48% share, followed by glass packaging at 28%, metal packaging at 11%, and rubber packaging at 7% [12]. Key Enterprises Analysis - The competitive landscape of the pharmaceutical packaging industry is diverse and intense. Key players include Shandong Pharmaceutical Glass, Zhengchuan Co., Hualan Co., Haishun New Materials, and Huqiang Technology, each with unique strengths and market positions [15][18][20]. Future Development Trends - The industry is moving towards high-end and high-performance packaging materials, focusing on new technologies and innovative designs to meet the demands of high-end pharmaceuticals [22]. - Green and environmentally friendly packaging is becoming a significant trend, with companies seeking biodegradable and recyclable materials to reduce environmental impact [23]. - The industry is also undergoing consolidation and internationalization, with companies optimizing resources and expanding into international markets to enhance competitiveness [24].

2024 年年度股东大会会议资料 证券代码：688151 证券简称：华强科技 湖北华强科技股份有限公司 2024 年年度股东大会 会议资料 二〇二五年五月 | 湖北华强科技股份有限公司 | 年年度股东大会会议须知 2024 | 1 | | --- | --- | --- | | 湖北华强科技股份有限公司 | 2024 年年度股东大会会议议程 | 4 | | 报告一： | | 7 | | 2024 | 年度独立董事述职报告（王广昌） | 7 | | 2024 | 年度独立董事述职报告（刘洪川） | 16 | | 2024 | 年度独立董事述职报告（刘景伟） | 25 | | 议案一 | ：2024 年度董事会工作报告 | 34 | | 议案二 | ：2024 年度监事会工作报告 | 50 | | 议案三 | ：2024 年年度报告全文及其摘要 | 55 | | 议案四 | ：2024 年度财务决算报告 | 56 | | 议案五 | ：2025 年度财务预算报告 | 63 | | 议案六 | ：2024 年度利润分配方案 | 65 | | 议案七 | ：关于预计 2025 年度日常关联交易的议案 | 67 | | ...

Group 1 - The core viewpoint of the news is that the military equipment restructuring concept has seen a significant increase, with a rise of 3.43%, ranking sixth among concept sectors [1][2] - Within the military equipment restructuring sector, seven stocks experienced gains, with Zhongguangxue hitting the daily limit, and other notable performers including Jianshe Industrial, Dong'an Power, and Hunan Tianyan, which rose by 5.39%, 2.54%, and 2.51% respectively [1][2] Group 2 - The military equipment restructuring sector attracted a net inflow of 152 million yuan from main funds today, with five stocks receiving net inflows [2][3] - Zhongguangxue led the net inflow with 63.15 million yuan, followed by Jianshe Industrial, Chang'an Automobile, and Changcheng Military Industry, which saw net inflows of 45.55 million yuan, 32.11 million yuan, and 11.35 million yuan respectively [2][3] - In terms of fund inflow ratios, Zhongguangxue, Jianshe Industrial, and Changcheng Military Industry had the highest net inflow rates at 28.81%, 7.91%, and 7.22% respectively [3]